![]() The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.įor more information, please visit aimimmunoand connect with the Company on Twitter, LinkedIn, and Facebook. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat. The webcast replay will be archived for 90 days following the event.ĪIM ImmunoTech Inc. AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders. AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. Ī video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 11 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company's website (aimimmuno). is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. For more information about the conference, please visit the conference website. AIMs flagship products include the Argentina-approved. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. 09, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers. Wainwright 25 th Annual Global Investment Conferenc being held September 11-13, 2023 in New York, NY and virtually. Get the latest AIM ImmunoTech Inc (AIM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Equels, Chief Executive Officer of AIM, will present at the H.C. ![]() (NYSE American: AIM) (“AIM” or the“Company”) today announced that Thomas K. Daily Vickers Top Buyers & Sellers for The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase. 05, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.( MENAFN- GlobeNewsWire - Nasdaq) OCALA, Fla., Sept. and changed its name to AIM ImmunoTech Inc. VistaGen Therapeutics (NASDAQ: VTGN) AIM ImmunoTech (NYSEAMERICAN: AIM) Tiziana Life Sciences (NASDAQ: TLSA) Senmiao. The company was formerly known as Hemispherx Biopharma, Inc. and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. has agreements with Amarex Clinical Research LLC Pharmaceutics International Inc. AIM ImmunoTech Inc (AIM) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |